InterK Peptide Therapeutics
Sydney, Australia· Est.
Australian biotech developing engineered immunomodulatory peptides for autoimmune, oncology, infectious and dermatology applications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian biotech developing engineered immunomodulatory peptides for autoimmune, oncology, infectious and dermatology applications.
ImmunologyOncologyInfectious DiseasesDermatology
Technology Platform
Engineered small, non‑naturally occurring peptides with backbone and side‑chain modifications to achieve high stability, selective immune modulation, and favorable pharmacokinetics.
Opportunities
Growing demand for novel immunomodulators and peptide therapeutics creates opportunities for partnerships and licensing deals.
Risk Factors
Pre‑clinical stage carries technical and regulatory uncertainty, and limited financial resources may delay clinical progression.
Competitive Landscape
InterK competes with biotech firms developing peptide‑based immunotherapies but differentiates through its focus on non‑natural peptide chemistry and multi‑indication applications.